Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2866-2873

  Prat, A ^a,b   Parker, J S ^a   Fan, C ^a   Cheang, M C U ^a   Miller, L D ^c   Bergh, J ^d,e   Chia, S K L ^f   Bernard, P S ^g   Nielsen, T O ^f,h   Ellis, M J ⁱ   Carey, L A ^a,j   Perou, C M ^a,j  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ USA   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Breast cancer; Genomics; Luminal; Mammaprint; Oncotype; PAM50

Indexed keywords

EID: 84868123650     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds080     Document Type: Article

References (32)

1. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2010; 5: 5-23.
2. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
3. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
4. Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
5. Fan C, Prat A, Parker J et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Medical Genomics 2010; 4: 3.
6. Cardoso F, Van't Veer L, Rutgers E et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26: 729-735.
7. Hammond MEH, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
8. Wang Y, Klijn J, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
9. Desmedt C, Piette F, Loi S et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007; 13: 3207-3214.
10. Parker JS, Mullins M, Cheang MCU et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
11. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
12. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569.
13. Oesterreich S, Lee AV, Davidson NE. Is it time to ReSET the standard for estrogen receptor testing in breast cancer?. J Clin Oncol 2010; 28: 4101-4103.
14. Oh DS, Troester MA, Usary J et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006; 24: 1656-1664.
15. Symmans WF, Hatzis C, Sotiriou C et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010; 28: 4111-4119.
16. Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-1246.
17. Loi S, Haibe-Kains B, Desmedt C et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008; 9: 239.
18. Zhang Y, Sieuwerts A, McGreevy M et al. The 76-gene signature defines highrisk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 2009; 116: 303-309.
19. Pawitan Y, Bjohle J, Amler L et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two populationbased cohorts. Breast Cancer Res 2005; 7: R953-R964.
20. Hess KR, Anderson K, Symmans WF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24: 4236-4244.
21. Perou C, Parker J, Prat A et al. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 2010; 11: 718-719.
22. Lusa L, McShane LM, Reid JF et al. Challenges in projecting clustering results across gene expression profiling datasets. J Natl Cancer Inst 2007; 99: 1715-1723
23. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.
24. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med 1997; 16: 385-395.
25. Harrell F, Lee K, Califf R et al. Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143-152.
26. Ellis M, Suman V, Hoog J et al. ACOSOG Z1031, a randomized phase 2 neoadjuvant comparison between letrozole, anastrozole and exemestane for postmenopausal women with ER rich stage 2/3 breast cancer: clinical and biomarker outcomes and the predictive value of the baseline PAM50-based intrinsic subtype. J Clin Oncol 2011; 29: 2342-2349.
27. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65.
28. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 2010; 28: 1829-1834.
29. Ellis MJ, Tao Y, Luo J et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100: 1380-1388.
30. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2011; 9148-57.
31. Landis J, Koch G. The measurement of observer agreement for catetgorical data. Biometrics 1977; 33: 159-174.
32. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721-728.